“PARP-1 Radiotracers for PET Imaging and Small Molecule Targeted Alpha Radiotherapeutics”

Hosted by the Mallinckrodt Institute of Radiology’s (MIR) PET Radiotracer Translation and Resource Center (PET-RTRC)

Abstract: PARP inhibitors (PARPi) have proven to be an important class of compounds for treating cancer patients having BRCA1/2 mutations or other deficiencies in homologous recombination repair. Unfortunately, ~50% of patients having BRCA1/2 mutations do not respond to PARPi, indicating that better biomarkers are needed to identify which patients are likely to benefit from this type of treatment. The first part of this presentation will focus on the use of [18F]Fluorthanatrace, a novel radiotracer for imaging PARP-1 expression levels, and how PET imaging studies with this radiotracer can provide clinically-relevant information regarding the use of PARP inhibitors in the treatment of cancer. The second part of the talk will focus on the use of an At-211 labeled PARPi as a small molecule targeted alpha emitter for treating cancers having a high expression of PARP-1.

For more information, please visit the PET-RTRC website.

For inquiries contact Michelle Hoelscher.